EQT Ventures leads USD 15 million seed round for Origin.Bio
Munich — EQT Ventures leads USD 15 million seed round for start up Origin.Bio. In addition to EQT Ventures, other backers include Blueyard and Inventures. DLA Piper advised EQT Ventures on its investment in the Munich-based start-up Origin.Bio in this seed round.
Since its founding in 2021, Origin.Bio, a synthetic biology company, has been connecting bioengineers with nature. It produces synthetic microorganisms that can produce many of the same substances that traditional chemical industry processes do today, but with significantly lower energy use and waste generation and avoiding petroleum chemicals. The company provides the link between R&D‑focused institutions and manufacturers and increased climate-focused innovation.
EQT Ventures is the venture capital fund of the Swedish private equity fund EQT Partners. EQT Ventures invests in fast-growing, innovative and technology-driven companies in all sectors worldwide, with a focus on Europe and the US.
Advisors to EQT Ventures: DLA Piper
The DLA Piper team, led by Partner Andreas Füchsel (Private Equity/M&A), continued to include Partner Semin O (Litigation & Regulatory), Counsel Kaja Herrmann (Labor Law), Senior Associate Philipp Groll (Private Equity/M&A) and Associates Alexander Rösch (Litigation & Regulatory), Johannes Klug (Labor Law, all Frankfurt) and Jessica Herrmann (Corporate, Munich).
About DLA Piper
DLA Piper is one of the world’s leading commercial law firms, with offices in more than 40 countries in Africa, Asia, Australia, Europe, the Middle East, and North and South America. In Germany, DLA Piper is represented by more than 240 lawyers at its offices in Frankfurt, Hamburg, Cologne and Munich. In certain jurisdictions, this information may be considered attorney advertising. www.dlapiper.com